(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 5.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.78%.
Vertex Pharmaceuticals's revenue in 2023 is $8,930,700,000.On average, 10 Wall Street analysts forecast VRTX's revenue for 2023 to be $2,394,031,642,220, with the lowest VRTX revenue forecast at $2,311,097,799,725, and the highest VRTX revenue forecast at $2,494,146,905,717. On average, 9 Wall Street analysts forecast VRTX's revenue for 2024 to be $2,545,319,928,683, with the lowest VRTX revenue forecast at $2,416,145,362,518, and the highest VRTX revenue forecast at $2,672,259,856,042.
In 2025, VRTX is forecast to generate $2,717,314,102,712 in revenue, with the lowest revenue forecast at $2,492,758,611,936 and the highest revenue forecast at $2,839,806,348,142.